Literature DB >> 192260

Cold lymphocytotoxic antibodies in nasopharyngeal carcinoma.

J P Lamelin, J P Revillard, J M Chalopin, J H Ho, T Souissi, G Schwaab, G De-Thé.   

Abstract

Sera from patients with nasopharyngeal carcinoma (NPC), a disease associated with Epstein-Barr virus (EBV), were found to be cytotoxic at 15% degrees C in the presence of complement for a panel of human lymphocytes, with a higher frequency than those of matched controls. The cold lymphocytotoxic antibodies (LTA) responsible for this activity have the same properties as those described in sera from individuals with acute viral infections. The frequency and geometric mean titres (GMT) of LTA varied with the origin of the patient (Chinese larger than North African larger than Caucasian) and the stage of the disease (Stage IV larger than Stage I). A positive correlation between LTA and anti-EBV titres was found with regard to antibodies to the viral capsid antigen (VCA) and the EBV-specified nuclear antigen (EBNA). The absence of correlation between LTA and anti-early antigen (EA) titres probable reflects the complex relationships existing between viral infection and LTA production, but is compatible with the hypothesis that LTA acts as an immune regulatory mechanism in viral infections.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 192260      PMCID: PMC2025356          DOI: 10.1038/bjc.1977.64

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other ebv antigens in chinese patients.

Authors:  G de-Thé; J H Ho; D V Ablashi; N E Day; A J Macario; M C Martin-Berthelon; G Pearson; R Sohier
Journal:  Int J Cancer       Date:  1975-11-15       Impact factor: 7.396

2.  Nasopharyngeal carcinoma. X. Presence of epstein-barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya.

Authors:  C Desgranges; H Wolf; G De-Thé; K Shanmugaratnam; N Cammoun; R Ellouz; G Klein; K Lennert; N Muñoz; H Zur Hausen
Journal:  Int J Cancer       Date:  1975-07-15       Impact factor: 7.396

3.  Impaired general cell-mediated immune functions in vivo and in vitro in patients with nasopharyngeal carcinoma.

Authors:  S H Chan; T S Chew; E H Goh; M J Simons; K Shanmugaratnam
Journal:  Int J Cancer       Date:  1976-08-15       Impact factor: 7.396

4.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

5.  HL-A, immune-response genes, and disease.

Authors:  H O McDevitt; W F Bodmer
Journal:  Lancet       Date:  1974-06-22       Impact factor: 79.321

6.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

7.  Anti-nucleic acid antibodies in systemic lupus erythematosus patients and their families. Incidence and correlation with lymphocytotoxic antibodies.

Authors:  R J DeHoratius; R Pillarisetty; R P Messner; N Talal
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

8.  Analyses of lymphocytes from patients with rheumatoid arthritis and systemic lupus erythematosus. Occurrence of interfering cold-reactive antilymphocyte antibodies.

Authors:  R J Winchester; J B Winfield; F Siegal; P Wernet; Z Bentwich; H G Kunkel
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

9.  Probable identification of an HL-A second-locus antigen associated with a high risk of nasopharyngeal carcinoma.

Authors:  M J Simons; G B Wee; S H Chan; K Shanmugaratnam
Journal:  Lancet       Date:  1975-01-18       Impact factor: 79.321

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.